Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

Sabra Health Care REIT rated buy, undervalued compared to peers. Investment-grade ratings, +7% dividend yield opportunity.

With cross currents jostling the markets and a knowledge of history, we were quick to sell. And quick to buy back.

MicroStrategy has revealed plans to raise up to $2 billion through public offerings to buy more Bitcoin for its treasury.

SoFi Technologies' recent 10% share price decline is justified due to overvaluation, despite a 120% rise over the last six ...

Bitcoin (BTC), the world’s largest cryptocurrency, outperforms every other major asset class globally, with an annual growth ...

The Nasdaq was down more than 2% and the S&P 500 lost 1.5% as Big Tech led the day's declines ...

With the business potentially at an important milestone, we thought we'd take a closer look at Rocket Lab USA, ...

The same goes for the Nasdaq 100 Index, with only 4.1% weight overlap. Another point worth mentioning is that the fund is ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

An analyst has observed that Bitcoin may not be on the verge of a bear market based on historical price movements.

UroGen Pharma Ltd. ( NASDAQ:URGN ) is possibly approaching a major achievement in its business, so we would like ...